Methods of treating fibrosis
AssigneeEndeavor BioMedicines, Inc.
InventorsMiguel de los Rios, John Hood, Anita DiFrancesco, Luis A. Dellamary
Life of this patent
Estimating the term…
Abstract
The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.
Claims26
A method of treating idiopathic pulmonary fibrosis, the method comprising administering a dose of taladegib, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the dose of taladegib is selected from a dose in the range of 50 mg to 200 mg.
A method of treating idiopathic pulmonary fibrosis, the method comprising administering a dose of taladegib, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the dose of taladegib is selected from a dose in the range of 100 mg to 300 mg.
A method of treating idiopathic pulmonary fibrosis, the method comprising administering a dose of taladegib, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the dose of taladegib is selected from 25, 50, 75, 100, 150, 200, 250, 300, 350, and 400 mg.
Dependencies are inferred from the claim text.